Newsbenzinga
Eli Lilly CFO Says Injectable GLP-1 Drugs Remain Key Growth Driver, Account For Three Out Of Four New Patient Starts
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Comments —
Loading comments…